A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 5 sites in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 84th largest by enrollment, is one of 14 that started in 2011, is one of 65 in phase 3, and was the 54th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 14 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 110th largest by enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2011, is one of 85 in phase 3, and was the 109th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with active rheumatoid arthritis who have an inadequate response to non-biologic disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for a total of 6 infusions plus methotrexate 10-25 mg orally weekly. Anticipated time on study treatment is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra] · Drug: methotrexate
Drug page: Tocilizumab
8 mg/kg iv every 4 weeks for a total of 6 infusions
10-25 mg orally weekly
Percentage of Participants Achieving Low Disease Activity Score
Disease Activity Score using 28-Joint Count (DAS28) was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog scale \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
Time frame: Week 24
Time to Achieve Low Disease Activity (DAS28 ≤3.2)
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity; time to low disease activity was calculated as the time in weeks from the date of first infusion to the first achievement of DAS28 ≤3.2
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With a Clinically Significant Improvement in DAS28 Score
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement in DAS28 score was defined as a reduction of at least 1.2 units.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Time to Clinically Significant Improvement in DAS28
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement is a reduction in DAS28 score of at least 1.2 units. Time to clinically significant improvement was determined in weeks from the date of first infusion to the date of first achievement of reduction of 1.2 units in DAS28.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving DAS28 Remission (DAS28 <2.6)
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Remission was defined as DAS28 \<2.6.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24
Time to Achieve DAS28 Remission (DAS28 <2.6)
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 remission was defined as DAS28 \<2.6. Time to achieve remission was calculated in weeks as the time from the date of first infusion to the date of first achieving remission.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants With DAS28 <3.2 by Visit
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving American College of Rheumatology (ACR) 20%, 50%, and 70% Improvement (ACR20, ACR50, or ACR70) Response
ACR20/50/70 response was defined as ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) as well as improvement in at least 3 of the 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the health assessment questionnaire \[HAQ\]); and acute phase response: C-reactive protein (CRP) or ESR.
Time frame: Week 24
Erythrocyte Sedimentation Rate
Erythrocyte Sedimentation rate was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
C-Reactive Protein Levels
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Time frame: Baseline, Weeks 4, 8, 12,16, 20, and 24
| Milestone | Tocilizumab + Methotrexate (MTX) |
|---|---|
| Started | 39 |
| Completed | 35 |
| Not completed | 4 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 1 |
Disease Activity Score using 28-Joint Count (DAS28) was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog scale \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
| percentage of participants | Tocilizumab + MTX |
|---|---|
| Percentage of Participants Achieving Low Disease Activity Score | 100 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity; time to low disease activity was calculated as the time in weeks from the date of first infusion to the first achievement of DAS28 ≤3.2
| weeks | Tocilizumab + MTX |
|---|---|
| Time to Achieve Low Disease Activity (DAS28 ≤3.2) | 9.5 ± 5.3 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement in DAS28 score was defined as a reduction of at least 1.2 units.
| percentage of participants | Tocilizumab + MTX |
|---|---|
| Week 4 | 87.2 |
| Week 8 | 91.9 |
| Week 12 | 94.7 |
| Week 16 | 97.3 |
| Week 20 | 97.3 |
| Week 24 | 100 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity; a clinically significant improvement is a reduction in DAS28 score of at least 1.2 units. Time to clinically significant improvement was determined in weeks from the date of first infusion to the date of first achievement of reduction of 1.2 units in DAS28.
| weeks | Tocilizumab + MTX |
|---|---|
| Time to Clinically Significant Improvement in DAS28 | 12.5 ± 6.3 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Remission was defined as DAS28 \<2.6.
| percentage of participants | Tocilizumab + MTX |
|---|---|
| Baseline | 0.0 |
| Week 4 | 20.5 |
| Week 8 | 36.8 |
| Week 12 | 44.7 |
| Week 16 | 59.0 |
| Week 20 | 74.4 |
| Week 24 | 82.1 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 remission was defined as DAS28 \<2.6. Time to achieve remission was calculated in weeks as the time from the date of first infusion to the date of first achieving remission.
| weeks | Tocilizumab + MTX |
|---|---|
| Time to Achieve DAS28 Remission (DAS28 <2.6) | 4.4 ± 1.6 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
| percentage of participants | Tocilizumab + MTX |
|---|---|
| Baseline | 0.0 |
| Week 4 | 30.8 |
| Week 8 | 48.7 |
| Week 12 | 69.2 |
| Week 16 | 82.1 |
| Week 20 | 89.7 |
| Week 24 | 100 |
ACR20/50/70 response was defined as ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) as well as improvement in at least 3 of the 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the health assessment questionnaire \[HAQ\]); and acute phase response: C-reactive protein (CRP) or ESR.
| percentage of participants | Tocilizumab + MTX |
|---|---|
| ACR20 | 20 |
| ACR50 | 34 |
| ACR70 | 34 |
Erythrocyte Sedimentation rate was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
| mm/hr | Tocilizumab + MTX |
|---|---|
| Baseline | 48.1 ± 26.1 |
| Week 4 | 10.7 ± 13.5 |
| Week 8 | 9.1 ± 10.5 |
| Week 12 | 6.3 ± 4.3 |
| Week 16 | 8.3 ± 8.3 |
| Week 20 | 6.6 ± 4.3 |
| Week 24 | 5.8 ± 3.3 |
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
| mg/L | Tocilizumab + MTX |
|---|---|
| Baseline | 17.6 ± 21.6 |
| Week 4 | 2.1 ± 8.5 |
| Week 8 | 0.8 ± 1.9 |
| Week 12 | 0.5 ± 1.0 |
| Week 16 | 1.2 ± 4.4 |
| Week 20 | 1.0 ± 2.6 |
| Week 24 | 0.4 ± 0.3 |
Collected over Adverse events were recorded from the day of baseline evaluation until the end of study at Week 24.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab + MTX | — | 2/39 (5.1%) | 37/39 (94.9%) |
| Event | Tocilizumab + MTX |
|---|---|
| SepsisInfections and infestations | 1/39 |
| Pulmonary tuberculosisInfections and infestations | 1/39 |
| Event | Tocilizumab + MTX |
|---|---|
| Hepatic enzyme increasedInvestigations | 12/39 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 9/39 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/39 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/39 |
| StomatitisGastrointestinal disorders | 5/39 |
| Pain ankleMusculoskeletal and connective tissue disorders | 5/39 |
| DyspepsiaGastrointestinal disorders | 3/39 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/39 |
| InfluenzaRespiratory, thoracic and mediastinal disorders | 3/39 |
| HeadacheNervous system disorders | 3/39 |
Intent to treat (ITT) population: all participants included in the study who received at least one dose of study medication. Participants prematurely withdrawn from the study will be considered as nonresponders at the end of the study in all analyses of treatment response variables.
| Age, Continuous(years) | Tocilizumab + MTX |
|---|---|
| Median | 53 (19 to 75) |
| Sex: Female, Male(Participants) | Tocilizumab + MTX |
|---|---|
| Female | 36 |
| Male | 3 |
The record gives a start of Mar 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Methotrexate